{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:58:28Z","timestamp":1782856708962,"version":"3.54.5"},"reference-count":95,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Canine atopic dermatitis is a hereditary chronic inflammatory and pruritic skin disease, which is mediated by T cells and requires long-term, individualized management. In recent years, numerous studies have described a wide range of therapeutic approaches for canine atopic dermatitis, including fast-acting symptomatic treatments, long-term immune-modulating interventions, and strategies to support skin barrier function and microbial balance. This review summarizes the principal treatment modalities currently available, including glucocorticoids, cyclosporine A, mycophenolate, Janus kinase inhibitors, lokivetmab, and allergen-specific immunotherapy, as well as complementary strategies aimed at restoring skin barrier integrity. Emphasis is placed on the importance of a multimodal and personalized approach to optimize long-term disease control and improve quality of life in affected dogs. Providing an integrated overview of current evidence, this article aims to guide clinicians in making informed, evidence-based decisions and to support the safe and effective management of canine atopic dermatitis.<\/jats:p>","DOI":"10.3390\/vetsci13040403","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:37:42Z","timestamp":1776677862000},"page":"403","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis"],"prefix":"10.3390","volume":"13","author":[{"given":"Constantin-C\u0103t\u0103lin","family":"Mazilu","sequence":"first","affiliation":[{"name":"Internal Medicine Clinic, Faculty of Veterinary Medicine, Ia\u0219i University of Life Sciences, 8 M. Sadoveanu Alley, 700489 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-8977","authenticated-orcid":false,"given":"Anamaria-Hortensia","family":"Strichea","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic, Faculty of Veterinary Medicine, Ia\u0219i University of Life Sciences, 8 M. Sadoveanu Alley, 700489 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-9574","authenticated-orcid":false,"given":"Gheorghe","family":"Solcan","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic, Faculty of Veterinary Medicine, Ia\u0219i University of Life Sciences, 8 M. Sadoveanu Alley, 700489 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/vde.13183","article-title":"Introduction to the ICADA 2023 Canine Atopic Dermatitis Pathogenesis Review Articles and Updated Definition","volume":"35","author":"Eisenschenk","year":"2024","journal-title":"Vet. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/vde.13215","article-title":"Update on the Skin Barrier, Cutaneous Microbiome and Host Defence Peptides in Canine Atopic Dermatitis","volume":"35","author":"Santoro","year":"2024","journal-title":"Vet. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vetimm.2011.07.014","article-title":"Is the Skin Barrier Abnormal in Dogs with Atopic Dermatitis?","volume":"144","author":"Olivry","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1354\/vp.38-6-720","article-title":"Electron Microscopic Observations of Stratum Corneum Intercellular Lipids in Normal and Atopic Dogs","volume":"38","author":"Inman","year":"2001","journal-title":"Vet. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00403-011-1120-5","article-title":"Atopic Dermatitis in Dogs Is Associated with a High Heterogeneity in the Distribution of Protein-Bound Lipids within the Stratum Corneum","volume":"303","author":"Popa","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-3164.2009.00847.x","article-title":"Increased Transepidermal Water Loss and Decreased Ceramide Content in Lesional and Non-Lesional Skin of Dogs with Atopic Dermatitis","volume":"20","author":"Shimada","year":"2009","journal-title":"Vet. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1600-0625.2011.01306.x","article-title":"Alteration of Stratum Corneum Ceramide Profiles in Spontaneous Canine Model of Atopic Dermatitis","volume":"20","author":"Yoon","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-3164.2009.00759.x","article-title":"Characterization and Quantification of Ceramides in the Nonlesional Skin of Canine Patients with Atopic Dermatitis Compared with Controls","volume":"20","author":"Reiter","year":"2009","journal-title":"Vet. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1523-1747.2002.01846.x","article-title":"Decreased Levels of Sphingosine, a Natural Antimicrobial Agent, May Be Associated with Vulnerability of the Stratum Corneum from Patients with Atopic Dermatitis to Colonization by Staphylococcus aureus","volume":"119","author":"Arikawa","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.2147\/IJGM.S542311","article-title":"Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review","volume":"18","author":"Chen","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_11","first-page":"1106","article-title":"Efficacy of a Lipid-Based Barrier Repair Formulation in Moderate-to-Severe Pediatric Atopic Dermatitis","volume":"8","author":"Sugarman","year":"2009","journal-title":"J. Drugs Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.anai.2022.01.012","article-title":"Optimizing Emollient Therapy for Skin Barrier Repair in Atopic Dermatitis","volume":"128","author":"Elias","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Stahl, J., Paps, J., B\u00e4umer, W., and Olivry, T. (2012). Dermatophagoides farinae House Dust Mite Allergen Challenges Reduce Stratum Corneum Ceramides in an Experimental Dog Model of Acute Atopic Dermatitis. Vet. Dermatol., 23.","DOI":"10.1111\/j.1365-3164.2012.01114.x"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Santoro, D., Marsella, R., Pucheu-Haston, C.M., Eisenschenk, M.N.C., Nuttall, T., and Bizikova, P. (2015). Review: Pathogenesis of canine atopic dermatitis: Skin barrier and host\u2013micro-organism interaction. Vet. Dermatol., 26.","DOI":"10.1111\/vde.12197"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/vde.12366","article-title":"The Skin Microbiome in Allergen-induced Canine Atopic Dermatitis","volume":"27","author":"Pierezan","year":"2016","journal-title":"Vet. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Weese, J.S. (2013). The Canine and Feline Skin Microbiome in Health and Disease. Vet. Dermatol., 24.","DOI":"10.1111\/j.1365-3164.2012.01076.x"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13671-018-0232-y","article-title":"Skin Barrier Function and Atopic Dermatitis","volume":"7","author":"Rerknimitr","year":"2018","journal-title":"Curr. Derm. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_19","unstructured":"(2026, April 06). Available online: https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2018\/01\/TVP-2018-0102_Banovic_Canine-Atopic-Dermatitis_11.pdf."},{"key":"ref_20","first-page":"15","article-title":"Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies","volume":"15","author":"Drechsler","year":"2024","journal-title":"Vet. Med. Res. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Olivry, T., Saridomichelakis, M., Nuttall, T., Bensignor, E., Griffin, C.E., Hill, P.B., and International Committe on Allergic Diseases of Animals (ICADA) (2014). Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a Simplified Severity Scale for Assessing Skin Lesions of Atopic Dermatitis in Dogs. Vet. Dermatol., 25.","DOI":"10.1111\/vde.12107"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bruet, V., Mosca, M., Briand, A., Bourdeau, P., Pin, D., Cochet-Faivre, N., Cadiergues, M.-C., Bruet, V., Mosca, M., and Briand, A. (2022). Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs. Vet. Sci., 9.","DOI":"10.3390\/vetsci9040149"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gonzales, A.J., Fleck, T.J., Humphrey, W.R., Galvan, B.A., Aleo, M.M., Mahabir, S.P., Tena, J.-K., Greenwood, K.G., and McCall, R.B. (2016). IL-31-Induced Pruritus in Dogs: A Novel Experimental Model to Evaluate Anti-Pruritic Effects of Canine Therapeutics. Vet. Dermatol., 27.","DOI":"10.1111\/vde.12280"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Marsella, R., Ahrens, K., Wilkes, R., Trujillo, A., and Dorr, M. (2020). Comparison of Various Treatment Options for Canine Atopic Dermatitis: A Blinded, Randomized, Controlled Study in a Colony of Research Atopic Beagle Dogs. Vet. Dermatol., 31.","DOI":"10.1111\/vde.12849"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-3164.2009.00858.x","article-title":"The Glucocorticoid Sparing Efficacy of PhytopicaTM in the Management of Canine Atopic Dermatitis","volume":"21","author":"Schmidt","year":"2010","journal-title":"Vet. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-3164.2003.00318.x","article-title":"Comparison of Cyclosporine A with Methylprednisolone for Treatment of Canine Atopic Dermatitis: A Parallel, Blinded, Randomized Controlled Trial","volume":"14","author":"Steffan","year":"2003","journal-title":"Vet. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-3164.2009.00758.x","article-title":"A Prospective Study on the Clinical Features of Chronic Canine Atopic Dermatitis and Its Diagnosis","volume":"21","author":"Favrot","year":"2010","journal-title":"Vet. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0165-2427(01)00314-2","article-title":"The ACVD Task Force on Canine Atopic Dermatitis (XX): Glucocorticoid Pharmacotherapy","volume":"81","author":"Olivry","year":"2001","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cvsm.2022.01.009","article-title":"Glucocorticoids, Cyclosporine, Azathioprine, Chlorambucil, and Mycophenolate in Dogs and Cats: Clinical Uses, Pharmacology, and Side Effects","volume":"52","author":"Viviano","year":"2022","journal-title":"Vet. Clin. Small Anim. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2460\/ajvr.2002.63.408","article-title":"Multiple-Center Study of Reduced-Concentration Triamcinolone Topical Solution for the Treatment of Dogs with Known or Suspected Allergic Pruritus","volume":"63","author":"DeBoer","year":"2002","journal-title":"Am. J. Vet. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/vde.13298","article-title":"Canine Pigmented Viral Plaques Associated with Application of Potent Topical Glucocorticoids","volume":"36","author":"Denti","year":"2025","journal-title":"Vet. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"L\u00e9onard, C., Taminiau, B., Ngo, J., Fantini, O., Daube, G., and Fontaine, J. (2021). Preventive Use of a Topical Anti-Inflammatory Glucocorticoid in Atopic Dogs without Clinical Sign of Otitis Does Not Affect Ear Canal Microbiota and Mycobiota. Vet. Dermatol., 32.","DOI":"10.1111\/vde.12977"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/vde.70008","article-title":"Hydrocortisone Aceponate for Chronic Otitis: Long-Term Efficacy","volume":"36","year":"2025","journal-title":"Vet. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ramos, F.O., Filgueiras, R., Teixeira, M.A., Melo, L.H.A., Ara\u00fajo, M.R.F., Morgado, A.L.F., Lira, G.A., Gomes, M.E.N., Campos, L.R.S., and Melo, C.B. (2026). Long-Term Management of Recurrent Otitis Externa in Dogs Using a Two-Phase Protocol Involving Ciprofloxacin-Clotrimazole-Betamethasone and Topical Hydrocortisone Aceponate. BMC Vet. Res., 22.","DOI":"10.1186\/s12917-025-05200-1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/vde.13224","article-title":"Efficacy and Safety of a Hydrocortisone Aceponate-Containing Ear Spray Solution in Dogs with Erythemato-Ceruminous Otitis Externa: A Randomised, Multicentric, Single-Blinded, Controlled Trial","volume":"35","author":"Rigaut","year":"2024","journal-title":"Vet. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.yasa.2021.07.004","article-title":"Current Knowledge on Canine Atopic Dermatitis","volume":"2","author":"Outerbridge","year":"2021","journal-title":"Adv. Small Anim. Care"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dip, R., Carmichael, J., Letellier, I., Strehlau, G., Roberts, E., Bensignor, E., and Rosenkrantz, W. (2013). Concurrent Short-Term Use of Prednisolone with Cyclosporine A Accelerates Pruritus Reduction and Improvement in Clinical Scoring in Dogs with Atopic Dermatitis. BMC Vet. Res., 9.","DOI":"10.1186\/1746-6148-9-173"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-3164.2004.00376.x","article-title":"Cyclosporin A: A New Drug in the Field of Canine Dermatology","volume":"15","author":"Guaguere","year":"2004","journal-title":"Vet. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Marsella, R. (2021). Atopic Dermatitis in Domestic Animals: What Our Current Understanding Is and How This Applies to Clinical Practice. Vet. Sci., 8.","DOI":"10.3390\/vetsci8070124"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2460\/javma.2002.221.370","article-title":"Randomized Controlled Trial of the Efficacy of Cyclosporine in the Treatment of Atopic Dermatitis in Dogs","volume":"221","author":"Olivry","year":"2002","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-3164.2002.00283.x","article-title":"Cyclosporine Decreases Skin Lesions and Pruritus in Dogs with Atopic Dermatitis: A Blinded Randomized Prednisolone-controlled Trial*","volume":"13","author":"Olivry","year":"2002","journal-title":"Vet. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1751-0813.2004.tb12153.x","article-title":"Efficacy of Cyclosporin in the Treatment of Atopic Dermatitis in Dogs\u2014Combined Results from Two Veterinary Dermatology Referral Centres","volume":"82","author":"Burton","year":"2004","journal-title":"Aust. Vet. J."},{"key":"ref_43","first-page":"1283","article-title":"The Prevalence of Bacterial Infections during Cyclosporine Therapy in Dogs: A Critically Appraised Topic","volume":"61","author":"High","year":"2020","journal-title":"Can. Vet. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/vr.102471","article-title":"Life-Long Diseases Need Life-Long Treatment: Long-Term Safety of Ciclosporin in Canine Atopic Dermatitis","volume":"174","author":"Nuttall","year":"2014","journal-title":"Vet. Rec."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/pets1030024","article-title":"Influence of Feeding on IL-2 Gene Expression and Peak Blood Cyclosporine Concentration in Healthy Dogs Administered Oral Cyclosporine","volume":"1","author":"Pan","year":"2024","journal-title":"Pets"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-3164.2005.00491.x","article-title":"A Systematic Review and Meta-analysis of the Efficacy and Safety of Cyclosporin for the Treatment of Atopic Dermatitis in Dogs","volume":"17","author":"Steffan","year":"2006","journal-title":"Vet. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tvjl.2013.02.018","article-title":"Efficacy of a New Topical Cyclosporine A Formulation in the Treatment of Atopic Dermatitis in Dogs","volume":"197","author":"Puigdemont","year":"2013","journal-title":"Vet. J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ackermann, A.L., May, E.R., and Frank, L.A. (2017). Use of Mycophenolate Mofetil to Treat Immune-Mediated Skin Disease in 14 Dogs\u2014A Retrospective Evaluation. Vet. Dermatol., 28.","DOI":"10.1111\/vde.12400"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100755","DOI":"10.1016\/j.tcam.2022.100755","article-title":"Successful Treatment With Prednisolone and Mycophenolate Mofetil in a Dog With Recurrent Erythema Multiforme Minor","volume":"52","author":"Yun","year":"2023","journal-title":"Top. Companion Anim. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/vde.13283","article-title":"Treatment of Moderate-to-Severe Canine Atopic Dermatitis with Modified-Release Mycophenolate (OKV-1001): A Pilot Open-Label, Single-Arm Multicentric Clinical Trial","volume":"35","author":"Klotsman","year":"2024","journal-title":"Vet. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"De Caro Martins, G., da Costa-Val, A.P., Coura, F.M., Diamantino, G.M.L., Nogueira, M.M., de Oliveira Melo-Junior, O.A., Giunchetti, R.C., da Silveira-Lemos, D., and Melo, M.M. (2022). Immunomodulatory Effect of Long-Term Oclacitinib Maleate Therapy in Dogs with Atopic Dermatitis. Vet. Dermatol., 33.","DOI":"10.1111\/vde.13037"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.2460\/javma.22.12.0570","article-title":"Oclacitinib 10 Years Later: Lessons Learned and Directions for the Future","volume":"261","author":"Marsella","year":"2023","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Denti, D., Caldin, M., Ventura, L., and De Lucia, M. (2022). Prolonged Twice-Daily Administration of Oclacitinib for the Control of Canine Atopic Dermatitis: A Retrospective Study of 53 Client-Owned Atopic Dogs. Vet. Dermatol., 33.","DOI":"10.1111\/vde.13053"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Jasiecka-Miko\u0142ajczyk, A., Jaroszewski, J.J., and Ma\u015blanka, T. (2021). Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-\u03b3-, Producing Murine CD4+ and CD8+ T Cells and Counteracts the Induction of Type 1 Regulatory T Cells. Molecules, 26.","DOI":"10.3390\/molecules26185655"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-3164.2007.00616.x","article-title":"Development of an Owner-Assessed Scale to Measure the Severity of Pruritus in Dogs","volume":"18","author":"Hill","year":"2007","journal-title":"Vet. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cosgrove, S.B., Wren, J.A., Cleaver, D.M., Martin, D.D., Walsh, K.F., Harfst, J.A., Follis, S.L., King, V.L., Boucher, J.F., and Stegemann, M.R. (2013). Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet. Dermatol., 24.","DOI":"10.1111\/vde.12047"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jvp.13503","article-title":"Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs","volume":"48","author":"Nederveld","year":"2025","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Takahashi, J., Kanda, S., Imanishi, I., Hisano, T., Fukamachi, T., Taguchi, N., Momiyama, S., Nishiyama, S., Motegi, T., and Iyori, K. (2021). Efficacy and Safety of 0.0584% Hydrocortisone Aceponate Topical Spray and Systemic Oclacitinib Combination Therapy in Dogs with Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. Vet. Dermatol., 32.","DOI":"10.1111\/vde.12909"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/vde.13134","article-title":"A Randomised Controlled Trial Testing the Rebound-Preventing Benefit of Four Days of Prednisolone during the Induction of Oclacitinib Therapy in Dogs with Atopic Dermatitis","volume":"34","author":"Olivry","year":"2023","journal-title":"Vet. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"127","DOI":"10.17555\/jvc.2021.38.3.127","article-title":"Clinical Efficacy of Oclacitinib and Lokivetmab in Dogs with Canine Atopic Dermatitis","volume":"38","author":"Lee","year":"2021","journal-title":"J. Vet. Clin."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/vde.70034","article-title":"Efficacy of Combination Oclacitinib and Lokivetmab Therapies After Monotherapeutic Failure in 44 Dogs: A Retrospective Study","volume":"37","author":"Bachtel","year":"2026","journal-title":"Vet. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wichtowska, A., Olejnik, M., Wichtowska, A., and Olejnik, M. (2025). Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262210990"},{"key":"ref_63","unstructured":"Stock, M., Jirjis, F., Domann, V., Overbey, L., Cao, Q., and Kuhlmann, I. (2025). The Second-Generation Janus Kinase 1 Selective Inhibitor Atinvicitinib Is a Safe and Effective Once-Daily Treatment for Pruritus in Dogs with Allergic Dermatitis, unpublished."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kuntz, E.A., Gabor, L., and Toutain, C.E. (2025). Safety of Ilunocitinib Tablets (ZenreliaTM) after Once Daily Oral Administration in Dogs. BMC Vet. Res., 21.","DOI":"10.1186\/s12917-025-04579-1"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/vde.70009","article-title":"Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial","volume":"36","author":"Forster","year":"2025","journal-title":"Vet. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jvp.70022","article-title":"Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs","volume":"49","author":"Boerngen","year":"2026","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/vde.13319","article-title":"Comparative Efficacy and Safety of Ilunocitinib and Oclacitinib for the Control of Pruritus and Associated Skin Lesions in Dogs with Atopic Dermatitis","volume":"36","author":"Forster","year":"2025","journal-title":"Vet. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Fleck, T.J., Norris, L.R., Mahabir, S., Walters, R.R., Martinon, O., Dunham, S.A., and Gonzales, A.J. (2021). Onset and Duration of Action of Lokivetmab in a Canine Model of IL-31 Induced Pruritus. Vet. Dermatol., 32.","DOI":"10.1111\/vde.12943"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gober, M., Amodie, D., Mellencamp, M., and Hillier, A. (2025). Long Term Use of Lokivetmab (Cytopoint\u00ae) in Atopic Dogs. BMC Vet. Res., 21.","DOI":"10.1186\/s12917-025-04645-8"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/vde.13151","article-title":"Hair Cortisol Concentration, Disease Severity and Quality of Life in Dogs with Atopic Dermatitis during Lokivetmab Therapy","volume":"34","author":"Calesso","year":"2023","journal-title":"Vet. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.32932\/rpia.2022.03.075","article-title":"Efficacy and Safety of Lokivetmab (Cytopoint\u00ae) for the Control of Pruritus and Skin Lesions in Dogs with Atopic Dermatitis","volume":"30","author":"Pinto","year":"2022","journal-title":"Rev. Port. Imunoalergologia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/vde.13286","article-title":"Long-Term Use of Lokivetmab in Dogs with Atopic Dermatitis","volume":"35","author":"Kasper","year":"2024","journal-title":"Vet. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Van Brussel, L., Moyaert, H., Escalada, M., Mahabir, S.P., and Stegemann, M.R. (2021). A Masked, Randomised Clinical Trial Evaluating the Efficacy and Safety of Lokivetmab Compared to Saline Control in Client-Owned Dogs with Allergic Dermatitis. Vet. Dermatol., 32.","DOI":"10.1111\/vde.12984"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bensignor, E., and Videmont, E. (2022). Weekly Topical Therapy Based on Plant Extracts Combined with Lokivetmab in Canine Atopic Dermatitis. Vet. Dermatol., 33.","DOI":"10.1111\/vde.13004"},{"key":"ref_75","first-page":"933","article-title":"Canine Atopic Dermatitis\u2014Efficacy of Sublingual Immunotherapy","volume":"52","author":"Choi","year":"2024","journal-title":"Acta Sci. Vet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0165-2427(01)00348-8","article-title":"The ACVD Task Force on Canine Atopic Dermatitis (XXIV): Allergen-Specific Immunotherapy","volume":"81","author":"Griffin","year":"2001","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/vr.106024","article-title":"Allergen-Specific Immunotherapy in Dogs with Atopic Dermatitis: Is Owner Compliance the Main Success-Limiting Factor?","volume":"187","author":"Ferrer","year":"2020","journal-title":"Vet. Rec."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/vde.13170","article-title":"The Safety of Rush Immunotherapy in the Management of Canine Atopic Dermatitis\u2014230 Cases","volume":"34","author":"Weitzer","year":"2023","journal-title":"Vet. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/vde.13138","article-title":"A Randomised, Double-Blinded Comparison between Subcutaneous Rush and Intralympathic Allergen Immunotherapy Induction in Atopic Dogs","volume":"34","author":"Mueller","year":"2023","journal-title":"Vet. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Fennis, E.E.M., van Damme, C.M.M., Schlotter, Y.M., Sinke, J.D., Leistra, M.H.G., Bartels, R.T., and Broere, F. (2022). Efficacy of Subcutaneous Allergen Immunotherapy in Atopic Dogs: A Retrospective Study of 664 Cases. Vet. Dermatol., 33.","DOI":"10.1111\/vde.13075"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"123\u2013e49","DOI":"10.1111\/vde.12517","article-title":"Long-Term Effects of Intralymphatic Immunotherapy (ILIT) on Canine Atopic Dermatitis","volume":"29","author":"Timm","year":"2018","journal-title":"Vet. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Fischer, N.M., Favrot, C., Martini, F., and Rostaher, A. (2024). Intralymphatic Immunotherapy with Ultrasound Guidance Seems to Be Associated with Improved Clinical Effect in Canine Atopic Dermatitis\u2014A Retrospective Study of 109 Cases. Animals, 14.","DOI":"10.3390\/ani14202921"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/vde.12860","article-title":"A Comparative Study of Subcutaneous, Intralymphatic and Sublingual Immunotherapy for the Long-Term Control of Dogs with Nonseasonal Atopic Dermatitis","volume":"31","author":"Fischer","year":"2020","journal-title":"Vet. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Majewska, A., Dembele, K., Dziendzikowska, K., Prostek, A., Gajewska, M., Majewska, A., Dembele, K., Dziendzikowska, K., Prostek, A., and Gajewska, M. (2022). Cytokine and Lymphocyte Profiles in Dogs with Atopic Dermatitis after Allergen-Specific Immunotherapy. Vaccines, 10.","DOI":"10.3390\/vaccines10071037"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Id\u00e9e, A., Mosca, M., and Pin, D. (2022). Skin Barrier Reinforcement Effect Assessment of a Spot-on Based on Natural Ingredients in a Dog Model of Tape Stripping. Vet. Sci., 9.","DOI":"10.3390\/vetsci9080390"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Marsella, R. (2013). Fixing the Skin Barrier: Past, Present and Future\u2014Man and Dog Compared. Vet. Dermatol., 24.","DOI":"10.1111\/j.1365-3164.2012.01073.x"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/vde.70035","article-title":"A Novel Topical Emollient Plus for Canine Atopic Dermatitis: A Clinical Trial Assessing Efficacy and User Acceptance","volume":"37","author":"Fernandes","year":"2026","journal-title":"Vet. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Franco, J., Rajwa, B., Gomes, P., HogenEsch, H., Franco, J., Rajwa, B., Gomes, P., and HogenEsch, H. (2021). Local and Systemic Changes in Lipid Profile as Potential Biomarkers for Canine Atopic Dermatitis. Metabolites, 11.","DOI":"10.3390\/metabo11100670"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"76","DOI":"10.12968\/coan.2020.0018","article-title":"Topical Therapy in Canine Atopic Dermatitis: New Products","volume":"25","author":"Nuttall","year":"2020","journal-title":"Companion Anim."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Marsella, R., Segarra, S., Ahrens, K., Alonso, C., and Ferrer, L. (2020). Topical Treatment with SPHINGOLIPIDS and GLYCOSAMINOGLYCANS for Canine Atopic Dermatitis. BMC Vet. Res., 16.","DOI":"10.1186\/s12917-020-02306-6"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Loewinger, M., Wakshlag, J.J., Bowden, D., Peters-Kennedy, J., and Rosenberg, A. (2022). The Effect of a Mixed Cannabidiol and Cannabidiolic Acid Based Oil on Client-Owned Dogs with Atopic Dermatitis. Vet. Dermatol., 33.","DOI":"10.1111\/vde.13077"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Bensignor, E., Navarro, C., Gard, C., Jahier, B., Pressanti, C., Videmont, E., Bensignor, E., Navarro, C., Gard, C., and Jahier, B. (2024). Efficacy of Chlorhexidine Impregnated Wipes for the Local Dysbiosis in Atopic Dogs: A Multicentric Prospective Study. Vet. Sci., 11.","DOI":"10.3390\/vetsci11060240"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Esumi, M., Kanda, S., Shimoura, H., Hsiao, Y.-H., and Iyori, K. (2021). Preliminary Evaluation of Two Bathing Methods for the Management of Malassezia Overgrowth in Dogs with Atopic Dermatitis. Vet. Dermatol., 32.","DOI":"10.1111\/vde.12948"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Noli, C., Morelli, G., della Valle, M.F., Schievano, C., and Clinical Research Group (2024). Effects of a Protocol Combining a Non-Irritating Shampoo and an Adelmidrol-Based Adsorbent Mousse on Seborrhoea and Other Signs and Symptoms Secondary to Canine Atopic Dermatitis: A Multicenter, Open-Label Uncontrolled Clinical Trial. Vet. Sci., 11.","DOI":"10.3390\/vetsci11060229"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Santoro, D., Fagman, L., Zhang, Y., and Fahong, Y. (2021). Clinical Efficacy of Spray-Based Heat-Treated Lactobacilli in Canine Atopic Dermatitis: A Preliminary, Open-Label, Uncontrolled Study. Vet. Dermatol., 32.","DOI":"10.1111\/vde.12915"}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/4\/403\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:36:37Z","timestamp":1776681397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/4\/403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["vetsci13040403"],"URL":"https:\/\/doi.org\/10.3390\/vetsci13040403","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}